We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.68
Bid: 3.60
Ask: 3.76
Change: -0.18 (-4.66%)
Spread: 0.16 (4.444%)
Open: 3.86
High: 0.00
Low: 0.00
Prev. Close: 3.86
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PHC949 product registration submitted to the EPA

31 Jan 2022 07:00

RNS Number : 0579A
Plant Health Care PLC
31 January 2022
 

RNS

 

 

31 January 2022

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

PHC949 submitted for product registration in the USA

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, announces it has submitted a new application to the US Environmental Protection Agency (EPA) for registration of its novel peptide product, PHC949, for the control of damaging soil nematodes.

 

Highlights

- PHC949 is the second new product from Plant Health Care's PREtec (Vaccines for PlantsTM) technology platform; the Company plans one major new launch every year.

- The Company is targeting PHC949 against nematodes (soil pests), a market forecast to be worth $1.6 billion globally by 2025; these pests reduce crop yields by some $100 billion annually.

- In the USA, PHC949 is being co-developed with Wilbur-Ellis for nematode control in high-value specialty crops. Wilbur-Ellis, a $3.4bn distributor of crop inputs, plans to launch the product in the second half of 2023, soon after registration by the EPA.

- Field trials of PHC949 in the USA show outstanding control of nematodes; for example, in peppers PHC949 increased marketable yield by about 3,265 lbs/acre, worth an extra $2,070/acre.

- Field trials are also underway demonstrating the value of PHC949 in soybeans and other crops in the US and Brazil.

- The Company expects global sales of PHC949 to reach into the tens of millions of dollars over the long-term and to become a significant value driver for the Company.

 

Overview

PREtec peptides (Vaccines for Plants) represent a novel class of technology which stimulates the plant to defend itself. Derived from natural proteins, PREtec is an environmentally friendly approach to protecting crops and increasing yields. PREtec peptides support conventional farming to become more sustainable. The Company has invested more than $25 million in inventing and developing the PREtec platform over the last eight years and now plans to achieve at least one major launch of a PREtec product into a major market, every year.

 

Nematode pests are found in farmland worldwide and cause extensive damage to crops, reducing yields by approximately $100 billion annually. In California alone, nematode damage results in approximately $1.6 billion in annual yield losses for almond growers.

 

PHC949 enables plants to resist nematode infestation and leads to increased plant vigor and yield in a variety of crops. Unlike traditional chemical soil fumigants used to control nematodes, PHC949 leaves beneficial soil organisms unharmed.

 

The Company has now made a regulatory submission to the Environmental Protection Agency (EPA) for the use of PHC949 to control nematodes on a wide range of crops. The EPA's evaluation process is expected to take approximately 18 months.

 

The Company is working actively with Wilbur-Ellis to ready the product for launch, soon after the EPA issues commercial regulatory permits.

 

Plans are also underway to submit PHC949 in late 2022 for registration in Brazil, setting the stage for commercialization of PHC949 for use on soybeans in Brazil in 2024.

 

Chris Richards, CEO of Plant Health Care said; "We are pleased to have achieved this critical milestone in bringing PHC949 to market and are looking forward to commercial launch in the US after regulatory approval in 2023.

 

"Given the large number of chemical nematicides that have been withdrawn from the market by regulators because of environmental concerns, farmers are clamoring for sustainable solutions to protect their crops. I am confident therefore that PHC949 will be a valuable tool for growers, offering a cost-effective and environmentally friendly way to protect their crops from destructive nematodes.

 

"The regulatory submission of PHC949 follows the introduction of Saori® in Brazil during 2021 and the planned launch of PHC279 in the USA following regulatory approval later this year. With the submission of PHC949 in the USA, we are on target to achieve at least one major launch of a PREtec product, every year. We are excited about the potential for products based on our 'Vaccines for Plants' PREtec peptides, which are targeting markets valued in total at $5 billion."

 

For further information, please contact:

 

Plant Health Care plc

Chris Richards, CEO

+1 919 926 1600

 

Arden Partners plc - Nomad & Joint Broker

John Llewellyn-Lloyd / Antonio Bossi

+44 (0) 20 7614 5900

 

Cenkos Securities plc - Joint Broker

Neil McDonald / Peter Lynch

+44 (0) 20 7391 8900

 

Vox Markets - Digital Investor Relations

Paul Cornelius / Kat Perez

+44 (0) 7866 384707

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile. Find out more at Vox Markets and the company website: www.planthealthcare.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEBLFXLFLEBBX
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.